Richard Shimizu, MD
Internal Medicine · Springfield, MONPI 1164466645
Payments from drug & device makers
Across 740 payments — averaging $14.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Pfizer$1K
- Lilly USA, LLC$1K
- Novo Nordisk$631
- AbbVie$547
- plus $4K from 28 others
What the payments were for
- Food & beverage$10,811100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $1,836 |
| Boehringer Ingelheim | 99 | $1,332 |
| Pfizer | 97 | $1,187 |
| Lilly USA, LLC | 78 | $1,123 |
| Novo Nordisk | 44 | $631 |
| AbbVie(2 entities) | 50 | $547 |
| GSK | 34 | $523 |
| Abbott | 24 | $489 |
| Johnson & Johnson | 33 | $420 |
| Kowa Pharmaceuticals America, Inc. | 28 | $376 |
| Amgen | 24 | $346 |
| Sanofi | 15 | $292 |
| Merck | 19 | $244 |
| E.r. Squibb & Sons, L.L.C. | 14 | $204 |
| Dexcom, Inc. | 9 | $176 |
| Daiichi Sankyo Inc. | 9 | $167 |
| Biohaven Pharmaceuticals, Inc. | 12 | $143 |
| Upsher-smith Laboratories LLC | 6 | $109 |
| Amarin Pharma, Inc. | 7 | $109 |
| Axsome Therapeutics, Inc. | 3 | $86 |
| Radius Health, Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $56 |
| Bayer | 3 | $52 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Amneal Pharmaceuticals LLC | 3 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| Novartis | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Corium, LLC | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Eisai Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$10,818 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $95,584 |
| JardianceEmpagliflozin | 86 | $79,624 |
| FarxigaDapagliflozin Propanediol | 59 | $51,153 |
| JanuviaSitagliptin Phosphate | 27 | $31,469 |
| MounjaroTirzepatide | 27 | $28,519 |
| XareltoRivaroxaban | 33 | $24,666 |
| MyrbetriqMirabegron | 37 | $24,483 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $19,495 |
| TrulicityDulaglutide | 13 | $13,473 |
| LinzessLinaclotide | 17 | $8,602 |
| BelsomraSuvorexant | 16 | $8,111 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,175 |
| Arnuity ElliptaFluticasone Furoate | 12 | $6,460 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,770 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,283 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $1,187 | $100,867115 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $1,332 | $99,120112 claims |
| AstraZenecaFarxiga, Symbicort | $1,836 | $58,32980 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,123 | $41,99340 claims |
| MerckJanuvia, Belsomra | $244 | $39,58043 claims |
| Johnson & JohnsonXarelto | $420 | $24,66633 claims |
| GSKArnuity Ellipta, Incruse Ellipta, Arexvy, Shingrix | $523 | $19,70657 claims |
| AbbVieLinzess | $547 | $8,60217 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $56 | $2,73213 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $41 | $1,538237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Springfield
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.